January 14: The Week in Cancer News
Cancer mortality continues to go down, and a “real-world” study finds more than a third of active surveillance patients...
Cancer mortality continues to go down, and a “real-world” study finds more than a third of active surveillance patients...
The FDA Project Renewal initiative has updated the approved indications for temozolomide chemotherapy in anaplastic astrocytoma. The U.S. Food...
Researchers examine the “oral microbiome” to look for clues to cancer risk. In a continuing effort to better understand...
The FDA expanded the indications for pembrolizumab to include more patients with stage III-IVA cervical cancer. The U.S. Food...
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration...
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug...
Finding the latest discoveries in breast cancer care together. More than 7,000 breast cancer researchers, survivors, advocates, and others...
Researchers recently developed a risk prediction model that could categorize individuals with lung nodules as having high or low...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors. The...
The FDA approved the combination of an immune checkpoint inhibitor and a therapeutic that prevents tumors from growing blood...
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
The U.S. FDA approved a monoclonal antibody and enzyme combination for use in conjunction with chemotherapy and a steroid...
The U.S. FDA approved a combination of a molecularly targeted therapeutic and an immunotherapeutic to treat certain patients with...
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S....
Identifying people at the highest risk for pancreatic cancer could better identify those who should be screened to catch...
The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers...
The FDA approval is for the use of atezolizumab in combination with Abraxane for the treatment of certain patients...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
The U.S. Food and Drug Administration approval provides a new option for patients with liposarcoma and leiomyosarcoma that is...
The FDA has approved a combination of the immune checkpoint inhibitor atezolizumab with two targeted therapies for certain patients...
The FDA approved the molecularly targeted therapeutic tivozanib to treat certain adult patients with the most common type of...
The U.S. Food and Drug Administration approval provides a new option for patients whose disease is driven by mutations...
The FDA has approved nirogacestat for the treatment of noncancerous but painful growths called desmoid tumors. The U.S. Food...
the immunotherapeutic pembrolizumab in combination with chemotherapy WAS APPROVED to treat certain adult patients with esophageal cancer. The U.S....
The U.S. FDA approved a molecularly targeted therapeutic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug...
Non-invasive scanning for biomarkers after only 1 week may guide treatment for some patients with melanoma and avoid surgery...
Study presented at the AACR’s eighth annual cancer health disparities conference examines how improved diet reduced the risk of...
Screening gaps were largest among racial and ethnic minorities and socioeconomically disadvantaged individuals, study finds. Younger people are less...
Factors associated with the imaging facility, rather than individual characteristics, may explain some of these differences. The accuracy of...